| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
As a chemical reagent for oligonucleotide synthesis, 2'-O-MOE-5MeU-3'-phosphoramidite does not have a defined biological target. Its purpose is to serve as a building block for incorporating 2'-O-methoxyethyl-5-methyluridine residues into synthetic oligonucleotides. The 2'-MOE modification is one of the most widely used chemical modifications in therapeutic antisense oligonucleotides, providing enhanced nuclease resistance, improved binding affinity, and reduced immune stimulation.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, this phosphoramidite monomer is incorporated into oligonucleotide sequences during solid-phase synthesis. The resulting modified oligonucleotides containing 2'-MOE-5-methyluridine residues exhibit significantly enhanced stability against nuclease degradation and improved binding affinity to complementary RNA sequences. These properties make the monomer essential for the preparation of second-generation antisense oligonucleotides with improved therapeutic properties.
|
| ln Vivo |
This compound does not exhibit direct cellular activity as it is a chemical synthesis reagent rather than a bioactive molecule. Oligonucleotides synthesized using this monomer can be delivered into cells for various functional studies. The 2'-MOE modification enhances the metabolic stability and reduces the immune stimulatory potential of oligonucleotides in cellular environments. Antisense oligonucleotides containing 2'-MOE modifications are widely used for gene silencing applications. Cellular uptake typically occurs through endocytosis.
|
| Enzyme Assay |
The standard procedure for incorporating this phosphoramidite involves solid-phase oligonucleotide synthesis using standard phosphoramidite chemistry. The monomer is dissolved in anhydrous acetonitrile at 0.1 M concentration and coupled to the growing oligonucleotide chain using activator solutions such as tetrazole or 5-ethylthio-1H-tetrazole. Coupling times typically range from 2-5 minutes. Following chain assembly, the oligonucleotide is deprotected using ammonium hydroxide treatment to remove protecting groups.
|
| Cell Assay |
No cell-based experimental protocols are directly applicable to this phosphoramidite monomer as it is a chemical synthesis reagent. Oligonucleotides containing 2'-MOE-5-methyluridine residues synthesized using this monomer can be evaluated in cell culture experiments. Typical protocols include transfection of modified ASOs into mammalian cell lines at concentrations of 10-100 nM using lipid-based transfection reagents or gymnotic delivery. Cells are incubated for 24-72 hours, and target gene knockdown is assessed by qRT-PCR or Western blotting.
|
| Animal Protocol |
2'-O-MOE-5MeU-3'-phosphoramidite is not administered to animals as it is a chemical intermediate for oligonucleotide synthesis. Oligonucleotides containing 2'-MOE-5-methyluridine residues synthesized using this monomer are widely evaluated in animal models for therapeutic applications. Typical studies involve administration of modified ASOs to mice or rats via intravenous or subcutaneous routes at doses of 1-50 mg/kg. Pharmacodynamic endpoints include target gene silencing in tissues and therapeutic efficacy in disease models.
|
| ADME/Pharmacokinetics |
As a chemical reagent, this compound does not have established pharmacokinetic properties. Oligonucleotides containing 2'-MOE modifications exhibit significantly enhanced metabolic stability compared to unmodified or first-generation phosphorothioate oligonucleotides. The 2'-MOE modification increases resistance to nuclease degradation, resulting in plasma half-lives of several days. Biodistribution is predominantly to liver, kidney, and spleen. These properties have made 2'-MOE-modified ASOs successful in clinical development.
|
| Toxicity/Toxicokinetics |
The compound is not intended for therapeutic use and lacks established toxicity profiles. Standard laboratory safety precautions should be observed when handling this chemical reagent. Oligonucleotides containing 2'-MOE modifications generally exhibit improved safety profiles with reduced immune stimulation and hepatotoxicity compared to earlier generations of oligonucleotides. However, potential toxicities include injection site reactions, complement activation, and renal effects at high doses.
|
| Additional Infomation |
2'-O-MOE-5MeU-3'-phosphoramidite is a research-grade chemical supplied for oligonucleotide synthesis applications. It is not an approved pharmaceutical and has no clinical trial history as a standalone compound. The 2'-MOE modification is one of the most successful chemical modifications in therapeutic oligonucleotides, with multiple FDA-approved ASO drugs incorporating this chemistry. The compound is typically stored at -20°C under desiccated conditions. This product is for research use only and is not for human therapeutic applications.
|
| Molecular Formula |
C43H55N4O10P
|
|---|---|
| Molecular Weight |
818.89
|
| Exact Mass |
818.366
|
| CAS # |
163878-63-5
|
| PubChem CID |
92043625
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.461
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
58
|
| Complexity |
1340
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COC(C3=CC=CC=C3)(C4=CC=C(C=C4)OC)C5=CC=C(C=C5)OC)OP(N(C(C)C)C(C)C)OCCC#N)OCCOC
|
| InChi Key |
YFRRKZDUDXHJNC-KZQAAKLLSA-N
|
| InChi Code |
InChI=1S/C43H55N4O10P/c1-29(2)47(30(3)4)58(55-24-12-23-44)57-38-37(56-41(39(38)53-26-25-50-6)46-27-31(5)40(48)45-42(46)49)28-54-43(32-13-10-9-11-14-32,33-15-19-35(51-7)20-16-33)34-17-21-36(52-8)22-18-34/h9-11,13-22,27,29-30,37-39,41H,12,24-26,28H2,1-8H3,(H,45,48,49)/t37-,38-,39-,41-,58?/m1/s1
|
| Chemical Name |
3-[[(2R,3R,4R,5R)-2-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile
|
| Synonyms |
2'-O-MOE-5-ME-U phosphoramidite monomer; 2'-O-MOE-5-ME-U phosphoramidite monomer
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2212 mL | 6.1058 mL | 12.2117 mL | |
| 5 mM | 0.2442 mL | 1.2212 mL | 2.4423 mL | |
| 10 mM | 0.1221 mL | 0.6106 mL | 1.2212 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
